










































Admixture mapping of lung cancer in 1812 African-Americans
Citation for published version:
Schwartz, AG, Wenzlaff, AS, Bock, CH, Ruterbusch, JJ, Chen, W, Cote, ML, Artis, AS, Van Dyke, AL, Land,
SJ, Harris, CC, Pine, SR, Spitz, MR, Amos, CI, Levin, AM & McKeigue, PM 2011, 'Admixture mapping of
lung cancer in 1812 African-Americans' Carcinogenesis, vol. 32, no. 3, pp. 312-317. DOI:
10.1093/carcin/bgq252
Digital Object Identifier (DOI):
10.1093/carcin/bgq252
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Carcinogenesis vol.32 no.3 pp.312–317, 2011
doi:10.1093/carcin/bgq252
Advance Access publication November 29, 2010
Admixture mapping of lung cancer in 1812 African-Americans
Ann G.Schwartz1,2,, Angela S.Wenzlaff1,
Cathryn H.Bock1,2, Julie J.Ruterbusch1, Wei Chen1,2,
Michele L.Cote1,2, Amanda S.Artis1, Alison L.Van Dyke1,
Susan J.Land3, Curtis C.Harris4, Sharon R.Pine4,
Margaret R.Spitz5, Christopher I.Amos5, Albert M.Levin6
and Paul M.McKeigue7
1Karmanos Cancer Institute, 4100 John R, Detroit, MI 48201, USA,
2Department of Oncology, Wayne State University School of Medicine,
Detroit, MI 48201, USA, 3Applied Genomics Technology Center, Department
of Obstetrics and Gynecology, Wayne State University School of Medicine,
and Genomics Core, Karmanos Cancer Institute, Detroit, MI 48201, USA,
4Laboratory of Human Carcinogenesis, Center for Cancer Research, National
Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA,
5Department of Epidemiology, The University of Texas M. D. Anderson
Cancer Center, Houston, TX 77030, USA, 6Department of Biostatistics and
Research Epidemiology, Henry Ford Health System, Detroit, MI 48202, USA
and 7MRC Human Genetics Unit, University of Edinburgh, Western General
Hospital, Edinburgh, UK
To whom correspondence should be addressed. Tel: þ1 313 578 4201;
Fax: þ1 313 578 4306;
Email: schwarta@karmanos.org.
Lung cancer continues to be the leading cause of cancer death in
the USA and the best example of a cancer with undisputed evi-
dence of environmental risk. However, a genetic contribution to
lung cancer has also been demonstrated by studies of familial
aggregation, family-based linkage, candidate gene studies and
most recently genome-wide association studies (GWAS). The
African-American population has been underrepresented in these
genetic studies and has patterns of cigarette use and linkage
disequilibrium that differ from patterns in other populations.
Therefore, studies in African-Americans can provide complemen-
tary data to localize lung cancer susceptibility genes and explore
smoking dependence-related genes. We used admixture mapping
to further characterize genetic risk of lung cancer in a series of
837 African-American lung cancer cases and 975 African-
American controls genotyped at 1344 ancestry informative
single-nucleotide polymorphisms. Both case-only and case–
control analyses were conducted using ADMIXMAP adjusted
for age, sex, pack-years of smoking, family history of lung cancer,
history of emphysema and study site. In case-only analyses, excess
European ancestry was observed over a wide region on chromo-
some 1 with the largest excess seen at rs6587361 for non-small-cell
lung cancer (NSCLC) (Z-score5 24.33; P 5 1.5 3 1025) and for
women with NSCLC (Z-score 5 24.82; P 5 1.4 3 1026). Excess
African ancestry was also observed on chromosome 3q with a peak
Z-score of 3.33 (P5 0.0009) at rs181696 among ever smokers with
NSCLC. These results add to the findings from the GWAS in
Caucasian populations and suggest novel regions of interest.
Introduction
Lung cancer continues to be the leading cause of cancer death in the
USA (1) and the best example of a cancer with undisputed evidence of
environmental risk. Although 80– 90% of lung cancer incidence is
attributed to cigarette smoking, only 15% of smokers develop this
disease suggesting that there are individual differences in susceptibil-
ity. Differential risk is also seen by race; African-Americans tend to
smoke fewer cigarettes (2), yet have higher incidence rates for lung
cancer (1), and have higher risk associated with a family history of
lung cancer than Caucasians (3). Contributions to the understanding
of the genetic susceptibility to lung cancer risk have come from a
family-based linkage study (4), candidate gene studies (reviewed in
ref. 5) and genome-wide association studies (GWAS) (6–9) conducted
in primarily Caucasian populations. Studies of candidate genes have
produced mixed results (5), in part reflecting the small size of many of
these studies, leaving open the question of the contribution to risk
from common low-penetrant genes. The family linkage study and
the GWAS have identified several chromosomal regions of interest
including 6q23–25 (4), 15q25 (6–8) and 5p15 and 6p21 (10). The
15q25 region contains the nicotinic acetylcholine receptor subunit
genes CHRNA3 and CHRNA5 raising the possibility that these genes
indirectly affect lung cancer risk through smoking behavior (8,11)
versus a direct affect on lung cancer risk (6–9).
Examining genetic risk in African-Americans provides comple-
mentary data to localize lung cancer susceptibility genes and explore
smoking dependence-related genes because this population has dif-
ferent patterns of cigarette use and linkage disequilibrium (LD) than is
seen in other populations. Since admixture between Europeans and
Africans occurred relatively recently, large chromosomal regions of
European or African origin remain in admixture-induced LD. Admix-
ture mapping represents an alternative strategy for gene discovery that
benefits from the LD characteristics of admixed populations (12,13).
This chromosomal structure supports the use of ancestry informative
single-nucleotide polymorphisms (SNPs) as markers for disease genes
that occur differentially between populations of different origin. This
approach also requires fewer markers and smaller sample sizes than
GWAS (14,15). This study is the first to use admixture mapping to
further characterize genetic risk of lung cancer, taking advantage of
the higher risks for lung cancer in African-Americans compared with
Caucasians.
Materials and methods
Case and control populations
Institutional Review Board approval was obtained at all study sites and in-
formed consent was obtained from all participants. Cases and controls were
enrolled through three sites: Wayne State University (WSU), M. D. Anderson
Cancer Center (MDA) and the National Cancer Institute (NCI). WSU identi-
fied population-based cases through the Metropolitan Detroit Cancer Surveil-
lance System, a participant in the NCI’s Surveillance, Epidemiology and End
Results program. Three WSU studies were used in this analysis, all conducted
by the same study staff using identical procedures; studies differed only in the
eligibility of cases as detailed in other publications. The Family History Study
focused on never-smokers and cases diagnosed before age 50 years regardless
of smoking habits (16,17), the Women’s Epidemiology of Lung Diseases
study focused on non-small-cell lung cancer (NSCLC) in women (18,19)
and the Exploring Health, Ancestry and Lung Epidemiology (EXHALE) study
is ongoing and includes only African-Americans. With the exception of the
EXHALE study, population-based controls were chosen using random digit
dialing methods. The EXHALE study relies on volunteer controls identified as
friends of the cases and through advertising. All study controls were frequency
matched to cases by 5-year-age group, sex and self-reported race. In total,
444 African-American cases and 559 African-American controls from WSU
studies were included.
The MDA cases and controls were selected from a large hospital-based
case–control study. This population has been described in detail elsewhere
(20). Histopathologically confirmed lung cancer cases were recruited from
the University of Texas M. D. Anderson Cancer Center and the Michael E.
DeBakey VA Medical Center in Houston, TX. Controls were recruited from the
Kelsey–Seybold Foundation, a multispeciality physician group practice in the
Houston metropolitan area, and were matched to the cases on race, age
(±5 years) and sex. In total, 192 African-American cases and 188 African-
American controls from MDA were included.
The NCI cases and controls were selected from an ongoing case–control
study in Baltimore, MD. The study population and enrollment criteria have
Abbreviations: aRR, ancestry risk ratio; CEPH, Center d’Etude du Polymor-
phisme Humain; GWAS, genome-wide association studies; LD, linkage dis-
equilibrium; MDA, M. D. Anderson Cancer Center; NCI, National Cancer
Institute; NSCLC, non-small-cell lung cancer; SNP, single-nucleotide poly-
morphism; WSU, Wayne State University.
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been described previously (21). Histopathologically confirmed lung cancer
cases were recruited from seven hospitals in the Baltimore, Maryland metro-
politan area. Cancer-free population controls were collected through a list de-
rived from the Maryland Department of Transportation. Two hundred and one
African-American cases and 228 African-American controls were included
from the NCI study.
Genotyping
The WSU and NCI studies used commercially available kits to isolate DNA.
The Gentra AutoPure Kit (Qiagen, Valencia, CA) was used to extract DNA
from 932 whole blood samples and the Gentra Puregene Kit (Qiagen) was used
for 71 mouthwash and saliva samples from WSU. DNA was isolated from
whole blood for the NCI samples using the Flexi Gene DNA kit (Qiagen).
For the MDA samples, a standard protocol was used to isolate DNA from the
lymphocyte cell pellet collected from the buffy coat by centrifugation of whole
blood. Pellets were digested with proteinase K and RNase, and the DNA was
extracted with phenol and chloroform/isoamyl alcohol and then precipitated
with ethanol.
Concentrated DNA samples for 30 Center d’Etude du Polymorphisme
Humain (CEPH) individuals were purchased from the Coriell Institute for
Medical Research in Camden, NJ (http://ccr.coriell.org) and used for quality
control.
Genotyping was conducted for all samples at the WSU Applied Genomics
Technology Center. Isolated DNA samples were diluted to the optimal con-
centration of 75 ng/ll and were run on the commercially available African-
American Admixture Panel from Illumina (http://www.Illumina.com). This
panel contains 1509 genome-wide SNPs informative for West African versus
European ancestry. The Illumina BeadStudio platform was used to cluster the
genotypes and provide the completion rates for individual samples and a mea-
sure of the predicted accuracy of each SNP (gentrain score).
Quality control
A total of 1864 eligible samples were genotyped. Forty-one samples were
excluded after failure to meet sample quality checks (call rates ,95% or
low DNA concentration). An additional 11 samples had high European ances-
try estimates (.85% European ancestry) and were excluded due to potential
sample misclassification. Thus, a total of 1812 samples were eligible for
analysis.
In addition to excluding entire samples of poor quality, SNPs with poor
genotyping accuracy were excluded from all analyses using the following
criteria. First, SNPs were excluded from all analyses if they were in the lowest
5% of gentrain scores; the X chromosome SNPs had both poor gentrain scores
and high heterozygosity rates in men, so were excluded. Second, SNPs that
were out of Hardy–Weinberg equilibrium, as indicated by a P-value,1 105,
were excluded from analysis. Finally, SNPs with .15% of the genotypes
varying from the HapMap reported genotypes in 30 CEPH samples were
excluded. In the 1257 SNPs with HapMap genotypes available for comparison,
there was a concordance rate of 99.9% among the previously genotyped CEPH
samples compared with genotyping conducted in this study. After all exclu-
sions, 1344 SNPs were eligible for inclusion in the analyses.
Statistical analysis
Data from 1812 participants and 1344 SNPs were analyzed using ADMIX-
MAP software. This program fits a Bayesian probability model using a Markov
chain Monte Carlo algorithm to compare observed versus expected ancestry
across the genome conditional on a priori ancestral genotype frequencies.
Regions of excess European or African ancestry suggest that risk variants more
common in one of the ancestral populations might be present. Both case–
control and case-only analyses were conducted adjusting for age at diagnosis
for cases or age at interview for controls, sex, smoking pack-years, family
history of lung cancer, history of emphysema and study site. The case-only
test compares ancestry at each locus to overall ancestry. The case–control test
compares ancestry at each locus between cases and controls while adjusting for
individual admixture and covariates included in the model (http://homepages.
ed.ac.uk/pmckeigu/admixmap/manual_desc.html). West African Yoruban (YRI)
and CEPH Europeans from Utah (CEU) HapMap genotype results were used to
estimate prior allele frequencies for the ancestral populations. Analyses were
repeated stratified by sex, smoking status and histology type.
Results from the ADMIXMAP analyses are presented in terms of standard
normal Z statistics, ancestry risk ratios (aRRs) from case-only analyses,
ancestry odds ratios from case–control analyses and P-values. A negative
Z-score indicates excess European ancestry at a locus and a positive Z-score
indicates excess African ancestry at a locus among cases. Similarly, a risk ratio
or an odds ratio .1 indicates increased risk of lung cancer associated with
carrying two African alleles in comparison with no African alleles; values ,1
indicate reduced risk of lung cancer associated with carrying two African
alleles in comparison with no African alleles. Regions with an absolute value
Z-score of 3.00 or greater at multiple SNPs (P-value 0.0025) in the case-only
analysis were further evaluated by conducting repeat analyses that dropped the
SNP with the highest absolute Z-score to ensure that results were not driven by
a single SNP. Findings are presented for any SNP with an absolute value Z-
score  3.00 in the case-only analysis, which also demonstrated a similar
increase in ancestry in the case–control analysis. All SNPs included in these
analyses were a minimum of 200 kb apart with a median spacing of 1400 kb. In
areas with high absolute Z-scores, ADMIXMAP results evaluating residual LD
between SNPs were reviewed. As a result of this review, three SNPs that were
tightly linked to adjacent SNPs (score test for residual LD, P , 0.001) on
chromosome 1 were removed before final analysis. Additionally, ADMIXMAP
was run while excluding every other SNP in the chromosome 1 peak area. This
analysis continued to show a chromosome 1 peak that was reduced in size but
still very strong. Two-sided tests of significance were applied to case-only and
case–control analyses to capture both African and European alleles that may be
associated with increased risk of lung cancer.
Results
Table I describes the characteristics of cases and controls (overall and
by study site). In the entire sample, females were overrepresented
among both cases and controls. Collectively, cases were slightly older,
more probably to be smokers and smoked more than controls. Cases
and controls were well matched by sex for the WSU and NCI pop-
ulations; however, MDA cases and controls varied significantly. Over-
all, 17.9% of cases and 3.7% of controls reported an emphysema
diagnosis. Rates of emphysema did not differ significantly across
the studies. Adenocarcinoma occurred more frequently in the Detroit
population due to the overrepresentation of this histology type in one
of the WSU studies and squamous cell carcinoma was more prevalent
in the MDA and NCI populations. NSCLC comprised .95% of the
known histology types across all three studies. Smoking status did not
differ significantly across the studies (P 5 0.11); however, average
ancestry (P 5 0.0003), age (P , 0.0001) and sex (P , 0.0001) were
significantly different. The mean proportion of African ancestry in
cases and controls combined was 80.7% in the WSU study partici-
pants, 78.4% in the MDA participants and 78.8% for the NCI partic-
ipants. Overall, the population demonstrated six generations of
admixture per morgan, and the mean African ancestry did not differ
between cases and controls. The average percent information
extracted by the marker panel was 74.1%.
Table II displays the local ancestry results for the peak SNP (i.e. the
SNP with the highest absolute Z-score) from the case-only test in two
regions of suggestive ancestry association. These regions showed an
excess of either European or African ancestry in the case-only anal-
ysis that was supported by the corresponding case–control analysis.
The strongest evidence for ancestry association was for a region on
chromosome 1q42 that displayed excess European ancestry among
cases (Figure 1a). The peak occurred at rs6587361 for all subjects,
NSCLC only and ever smokers with NSCLC in the case-only analysis
(Table II). The maximum Z-score was 4.33 for NSCLC (P 5 1.5 
105), with carriers of two African alleles at this locus having a re-
duction in lung cancer risk of 0.49 (95% confidence interval 0.36–
0.68) in comparison with carriers of two European alleles after ad-
justment for covariates. Excess European ancestry was strongest in
women with NSCLC, with a maximum Z-score of 4.82 (P 5 1.4 
106) associated with rs6587361 (data not shown). Case–control anal-
ysis also indicated excess European ancestry; increased Z-scores for
the same SNP demonstrated a large difference in ancestry between the
cases and controls (Table II). Again, the association with European
ancestry in the case–control analyses was strongest in women with
NSCLC in an SNP immediately adjacent to and downstream from
rs6587361 (rs2045520, Z-score 5 3.93; P 5 8.5  105) (data
not shown). Analysis stratified on the most predominant histology
type, adenocarcinoma, revealed attenuated Z-scores for both the
case-only and case–control analyses. For adenocarcinomas, the peak
European ancestry was located at rs493950 (Table II).
The second region of suggestive ancestry association was indicated
by several SNPs included in a region of excess African ancestry on
chromosome 3q25 (Figure 1b). The maximum Z-score for the case-only
Admixture mapping of lung cancer
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Table I. Subject characteristics for 1812 African-American lung cancer cases and controls



























Male 373 (44.5) 401 (41.2) 0.14 163 (36.7) 202 (36.1) 0.85 110 (57.3) 84 (44.7) 0.01 100 (49.8) 115 (50.4) 0.89
Female 464 (55.5) 574 (59.8) 281 (63.3) 357 (63.9) 82 (42.7) 104 (55.3) 101 (50.2) 113 (49.6)
Mean age (SD) 61.8 (10.5) 60.0 (11.5) 0.0009 60.2 (10.8) 58.7 (11.4) 0.04 63.2 (9.3) 55.3 (11.3) ,0.0001 64.0 (10.3) 67.3 (8.2) 0.0003
Mean African ancestry (%) 80.1 79.4 0.16 80.8 80.6 0.75 78.2 78.5 0.83 80.6 77.2 0.003
Smoking status
Never 69 (8.2) 339 (34.8) ,0.0001 28 (6.3) 198 (35.4) ,0.0001 26 (13.5) 47 (25.0) ,0.0001 15 (7.5) 94 (41.2) ,0.0001
Ever 768 (91.8) 636 (65.2) 416 (93.7) 361 (64.6) 166 (86.5) 141 (75.0) 186 (92.5) 134 (58.8)
Mean pack-years (SD) (ever smokers) 38.3 (27.1) 23.7 (19.6) ,0.0001 36.4 (27.4) 24.0 (19.7) ,0.0001 41.6 (27.0) 24.6 (21.7) ,0.0001 39.7 (26.4) 21.9 (16.9) ,0.0001
History of emphysema
No 643 (76.8) 931 (95.5) ,0.0001 363 (81.8) 534 (95.5) ,0.0001 113 (58.0) 174 (92.6) ,0.0001 167 (83.1) 223 (97.8) ,0.0001
Yes 150 (17.9) 36 (3.7) 81 (18.2) 24 (4.3) 35 (18.2) 7 (3.7) 34 (16.9) 5 (2.2)
Unknown 44 (5.3) 8 (0.8) 0 1 (0.2) 44 (22.9) 7 (3.7) 0 0
Histology
Adenocarcinoma 350 (41.8) 232 (52.2) 87 (45.3) 31 (15.4)
Small cell carcinoma 35 (4.2) 24 (5.4) 11 (5.7) 0 (0)
Squamous cell carcinoma 172 (20.6) 87 (19.6) 52 (27.1) 33 (16.4)
Other NSCLC (including NSCLC, nos) 170 (20.3) 90 (20.3) 41 (21.4) 39 (19.4)
Unknown 110 (13.1) 11 (2.5) 1 (0.5) 98 (48.8)
Family history of lung cancer
No 653 (78.0) 838 (86.0) ,0.0001 343 (77.3) 487 (87.1) ,0.0001 147 (76.6) 159 (84.6) 0.05 163 (81.1) 192 (84.2) 0.39














analysis was associated with rs181696 among ever smokers with
NSCLC (Z-score 5 3.33; P 5 0.0009) (Table II). Carriers of two
African alleles at this locus have an increased lung cancer risk of
1.72 (95% confidence interval 1.25–2.37) compared with carriers of
two European alleles. Case–control analyses showed an increased risk
of lung cancer associated with African ancestry for many SNPs in the
region, including rs181696 (Z-score 5 3.22; P-value 5 0.0013). Anal-
ysis of adenocarcinoma cases again revealed a weaker association with
Table II. Admixture mapping peaks associated with risk of lung cancer
Regiona Strata Case-only Case–control
Z-scoreb P-value aRRb 95% CI Z-scoreb P-value aORb 95% CI
1q42.13 rs6587361
All cases 3.38 0.0007 0.61 0.45–0.81 2.26 0.0240 0.78 0.63–0.97
NSCLC 4.33 1.5  105 0.49 0.36–0.68 2.88 0.0040 0.72 0.57–0.90
NSCLC ever smokers 3.96 7.7  105 0.51 0.36–0.71 2.40 0.0164 0.74 0.58–0.95
rs493950
Adenocarcinoma 3.10 0.0019 0.49 0.31–0.77 2.41 0.0161 0.71 0.54–0.94
3q25.31 rs181696
All cases 2.72 0.0066 1.47 1.11–1.94 2.63 0.0086 1.34 1.08–1.67
NSCLC 3.22 0.0013 1.64 1.21–2.22 3.22 0.0013 1.46 1.16–1.84
NSCLC ever smokers 3.33 0.0009 1.72 1.25–2.37 2.90 0.0038 1.46 1.13–1.89
Adenocarcinoma 1.83 0.0680 1.48 0.97–2.25 2.51 0.0120 1.42 1.08–1.87
CI, confidence interval.
aResults are reported for the peak SNP identified in the case-only analysis.
bZ-scores, ancestry risk ratios (aRR) and ancestry odds ratios (aOR) are reported for analyses adjusted for age, sex, pack-years, family history of lung cancer (no/
yes), study (WSU, MDA or NCI) and personal history of emphysema (no/yes). Positive Z-scores and aRR/aORs . 1 indicate increased risk of lung cancer
associated with carrying two African ancestral alleles in comparison with no African alleles. Conversely, negative Z-scores and aRR/aORs, 1 indicate decreased
risk of lung cancer associated with carrying two African ancestral alleles in comparison with none, which is also interpretable as an increased risk of lung cancer
associated with carrying two European alleles in comparison with none.
Fig. 1. (a) Admixture mapping results (Z-scores) for case-only and case–control analyses of chromosome 1 for NSCLC. (b) Admixture mapping results (Z-scores)
for case-only and case–control analyses of chromosome 3 for NSCLC.
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ancestry for both the case-only and case–control analyses, with the
highest Z-score at rs181696 (Table II).
Supplementary Table I (available at Carcinogenesis Online) high-
lights additional SNPs that were found in the chromosomes 1 and 3
regions of interest in the NSCLC analysis, as well as two additional
regions on 6p24 and 15q12–13.
Discussion
In this admixture analysis of 1812 African-Americans, ADMIXMAP
results revealed ancestry associations at 1q42 and 3q25. Both of these
areas were identified by increased Z-scores in both the case-only and
case–control analyses. This is the first reported admixture analysis of
lung cancer.
For the excess European ancestry region on chromosome 1, the most
significant Z-scores were found near a gene that has been strongly
associated with lung cancer risk, Epoxide Hydrolase 1 (EPHX1),
located at 1q42.1 (http://www.ncbi.nlm.nih.gov/gene). This gene
metabolizes polycyclic aromatic hydrocarbons, which are found in
cigarette smoke as well as other sources. A meta-analysis by Kiyohara
showed a significantly decreased risk of lung cancer associated with
the low-activity variant of the exon 3 (Tyr113His) polymorphism
among whites (22). Only two studies of EPHX1 appear to have in-
cluded African-Americans (23,24). Wu et al. (24) did not find signif-
icant associations between either Tyr113His or His139Arg and lung
cancer among African-Americans. When London et al. (23) com-
bined these two polymorphisms, a small decrease in risk was associ-
ated with the predicted slow activity genotype. Neither of these two
more extensively studied SNPs was included in this admixture panel.
It is possible that these or other SNPs in this gene or in this region are
responsible for the association we see with lung cancer risk.
Excess African ancestry was displayed on chromosome 3q25.
Many studies have reported increased copy number in this region in
lung tumors (25). In a 2008 paper, Qian et al. (26) suggest many
possible candidate genes in this region, including the oncogene PIK3-
CA and report that multiple studies have shown amplification of the 3q
region to be much more probable in squamous cell carcinoma cases as
compared with adenocarcinoma cases. We did not have sufficient
numbers of squamous cell carcinoma cases (n 5 172) to repeat our
analyses in this subpopulation; however, our adenocarcinoma results
add support to this finding. When results were restricted to adenocar-
cinoma cases, Z-scores were significantly lower in this region.
Several recent GWAS for lung cancer have also identified potential
susceptibility gene regions at 15q15, 15q25, 5p15 and 6p21 (6–10,27).
Within our study, we found excess European ancestry at 6p24 and
excess African ancestry at 15q11–13 in the case–control analyses
(supplementary Table I is available at Carcinogenesis Online). These
areas are a large distance removed from the regions identified in
the GWAS (.17 Mb and .14 Mb for the 6p21 and 15q15 regions,
respectively). Potential genes of interest in the 15q11–13 region
include the genes encoding the inhibitory neurotransmitter GABA
receptor gamma 3 (GABRG3, rs8042276), receptor alpha 5 (GABRA5)
and receptor beta 3 (GABRB3). Although these 15q11–13 receptor
genes have yet to be linked to lung cancer risk or nicotine addiction,
GABRA gene clusters on chromosomes 4 and 5 have been associated
with nicotine dependence (28,29). Another potential candidate gene is
CHRNA7, located further downstream on chromosome 15q14. While
CHRNA3 and CHRNA5 were both identified as candidate genes in the
lung cancer GWAS, CHRNA7 was not. However, it has been shown to
be upregulated in lung cell lines exposed to the tobacco-specific
nitrosamine NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butonone)
and estrogen (30). CHRNA7 is a candidate gene for schizophrenia,
where it has been shown to be differentially expressed in smokers
compared with nonsmokers (31).
It is possible that we did not see significant associations in the
same areas as the GWAS mentioned above because those studies only
included white and Asian populations. Furthermore, the regions
identified using GWAS methods might be associated with lung cancer
risk but might not be as strongly linked to ancestry.
We report both case-only and case–control analysis because these
methods complement each other. The case-only analysis is more pow-
erful than the case–control analyses because it compares ancestry
estimates at a given locus with its inherent variability to the case’s
genome-wide ancestry, which has been estimated over many markers
to reduce variability (32). The case–control method compares the
admixture at a given locus between the cases and controls (32). Thus,
while our Z-scores were sometimes lower for the case–control results,
they validate the case-only results in these regions by ruling out the
possibility that the findings are due to selection in these regions
among African-Americans.
There are several strengths to this study. The admixture map-
ping approach to gene discovery is a powerful method that takes
advantage of the LD patterns among the recently admixed
African-American population so that fewer individuals and fewer
SNPs are required than for a GWAS. In addition, this study
focused on African-Americans, a population that is known to have
different smoking patterns and possibly different genetic risks
than white and Asian populations. Although racial differences in
LD and smoking behaviors warrant the inclusion of African-
Americans in genetic studies, few studies have been done in this
population.
A proposed cutoff for genome-wide statistical significance has been
suggested for admixture mapping studies in African-Americans at
P , 105 (33). In the case-only NSCLC strata, SNP rs6587361
(P 5 1.5  105) at the 1q42.13 locus approached this significance
level, and among women with NSCLC, rs6587361 (P 5 1.4  106)
met this threshold. Furthermore, we performed a post-hoc power cal-
culation based on the methods of Hoggart et al. (33) for the case-only
analysis. Based on the mean observed marker information (37.98) in
our sample across the marker map and a two-tailed genome-wide
significance threshold of 105, we had 80% power to detect an aRR
, 0.40 (or .2.52). This calculation indicates that the sample was
reasonably powered to detect the ancestry association signal observed
among NSCLC subjects at 1q42.13 (for SNP rs6587361, an aRR of
0.49 among NSCLC subjects overall and an aRR of 0.36 among
female NSCLC subjects). Taken together, these results indicate that
at 1q42.13, there is a suggestive ancestry association locus for
NSCLC.
The study has a large sample size with .1800 cases and controls
and used a well-developed set of ancestry informative markers.
Women made up 57% of the study population and were dispropor-
tionally represented in the WSU group due to the nature of one of
the WSU studies. It is possible that the findings in women are driven
by study site differences rather than a sex specific effect; however,
study stratified analyses did not support a study site-specific finding
(data not shown). The only histology categories with large enough
numbers for meaningful analyses were NSCLC and adenocarcinoma
and therefore, our results might not be generalizable to all histology
types. We also had too few never smoking cases for meaningful
analyses.
Lung cancer is one of the few cancers for which no substantial
progress has been made in early detection and treatment. Given that
it is the leading cause of death from cancer, it is exceedingly impor-
tant to better understand the underlying biology to develop targeted
treatments and to identify high-risk populations for targeted behav-
ioral interventions and access to developing screening methods. It is
probably that many genes contribute to an individual’s lung cancer
risk. Admixture mapping provides an alternative approach to the
identification of lung cancer susceptibility genes. New regions were
identified in this admixture study. These results add to the findings
from the GWAS in Caucasian populations and suggest novel candi-
date gene areas. These regions need to be confirmed in additional
studies with finer mapping.
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